Search

Your search keyword '"Luigi Bolondi"' showing total 106 results

Search Constraints

Start Over You searched for: Author "Luigi Bolondi" Remove constraint Author: "Luigi Bolondi" Language english Remove constraint Language: english
106 results on '"Luigi Bolondi"'

Search Results

1. Discriminatory changes in circulating metabolites as a predictor of hepatocellular cancer in patients with MAFLD

2. A Western Case of Intravascular Large B-Cell Lymphoma as Unusual Cause of Persistent Fever

3. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib

4. Autoimmune Hepatitis and Celiac Disease: Case Report Showing an Entero-Hepatic Link

5. Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC.

6. Erratum: Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma

7. Multiple abdominal abscesses complicated by severe sepsis as a result of occult Crohn’s disease

8. MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA

9. MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA

10. Hypoalbuminemia and Risk of Portal Vein Thrombosis in Cirrhosis

11. Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study)

12. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma

13. MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma

14. Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma

15. Brivanib in combination with Notch3 silencing shows potent activity in tumour models

16. A Western Case of Intravascular Large B-Cell Lymphoma as Unusual Cause of Persistent Fever

17. LncRNAs as novel players in hepatocellular carcinoma recurrence

18. Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register

19. Regorafenib for the treatment of hepatocellular carcinoma

20. From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma

21. Pathobiological and radiomic approach for hepatocellular carcinoma subclassification

22. Celiac disease diagnosed through screening programs in at-risk adults is not associated with worse adherence to the gluten-free diet and might protect from osteopenia/osteoporosis

23. Risk factors for three-month mortality after discharge in a cohort of non-oncologic hospitalized elderly patients: Results from the REPOSI study

24. Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma

25. A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease

26. Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study

27. Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma

28. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy

29. Defining aging phenotypes and related outcomes: Clues to recognize frailty in hospitalized older patients

30. In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis

31. Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials

32. Pattern of in-hospital changes in drug use in the older people from 2010 to 2016

33. Antipsychotic prescription and mortality in hospitalized older persons

34. Stereotactic body radiotherapy for patients with hepatocellular carcinoma and intermediate grade cirrhosis – Authors' reply

35. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib

36. MicroRNA involvement in hepatocellular carcinoma

37. Years of life that could be saved from prevention of hepatocellular carcinoma

38. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals

39. Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma

40. Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma

41. TP53/MicroRNA interplay in hepatocellular carcinoma

42. Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma

43. Indications for liver transplantation

44. DIAGNOSTIC ACCURACY OF LIVER AND SPLEEN STIFFNESS MEASUREMENT FOR PORTAL HYPERTENSION USING BIDIMENSIONAL SHEAR WEAVE ELASTOGRAPHY

45. Clinical and diagnostic aspects of gluten related disorders

46. Efficacy of radioembolization according to tumor morphology and portal vein thrombosis inintermediate-advanced hepatocellular carcinoma

47. p53/MDM2 Feed-back Loop Sustains miR-221 Expression and Dictates the Response to Anticancer Treatments in Hepatocellular Carcinoma

48. Heart failure and chronic kidney disease in a registry of internal medicine wards

49. A case of inflammatory ascites

50. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection

Catalog

Books, media, physical & digital resources